Eleni Chrysanthou
Phenotypic characterization of breast cancer: the role of CDC42
Chrysanthou, Eleni; Gorringe, Kylie L.; Joseph, Chitra; Craze, Madeleine L.; Nolan, Christopher C.; Diez-Rodriguez, Maria; Green, Andrew R.; Rakha, Emad A.; Ellis, Ian O.; Mukherjee, Abhik
Authors
Kylie L. Gorringe
Dr CHITRA JOSEPH CHITRA.JOSEPH@NOTTINGHAM.AC.UK
Research Fellow
Madeleine L. Craze
Christopher C. Nolan
Maria Diez-Rodriguez
Andrew R. Green
Emad A. Rakha
Ian O. Ellis
Dr ABHIK MUKHERJEE ABHIK.MUKHERJEE1@NOTTINGHAM.AC.UK
Clinical Associate Professor
Abstract
Purpose: The molecular landscape of breast cancer (BC), especially of the Luminal A subtype, remains to be fully delineated. Transcriptomic data shows that Luminal A tumours are enriched for aberrant expression of genes in the cell division control 42 homolog (CDC42) pathway. This study aims to investigate protein expression of CDC42 in BC and assess its clinicopathological significance.
Methods: Expression of CDC42 protein was examined by immunohistochemistry on tissue microarrays in a well characterised cohort of 895 early stage (I-IIIa) primary invasive BCs.
Results: CDC42 expression was observed in both the cytoplasm and nucleus of BC cells. High nuclear CDC42 expression demonstrated a significant correlation with ER positive, low-grade tumours and was more common in the lobular histological subtype (all p<0.001). In contrast, cytoplasmic CDC42 showed increased expression in the ductal subtype (p<0.001) and correlated with negative prognostic features such as larger size, higher grade (p<0.05), and higher Ki67 labelling index (p=0.001). Nuclear CDC42 expression was associated with a longer BC specific survival in all cases (p=0.025) and in luminal ER positive tumours (p=0.011). In multivariate analyses including size, grade, lymph node stage and intrinsic subtype, CDC42 was an independent prognostic factor (p=0.032).
Conclusion: The results indicate that CDC42 is important molecule in luminal BC, with prognostic significance.
Citation
Chrysanthou, E., Gorringe, K. L., Joseph, C., Craze, M. L., Nolan, C. C., Diez-Rodriguez, M., Green, A. R., Rakha, E. A., Ellis, I. O., & Mukherjee, A. (2017). Phenotypic characterization of breast cancer: the role of CDC42. Breast Cancer Research and Treatment, 164(2), https://doi.org/10.1007/s10549-017-4267-8
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 30, 2017 |
Online Publication Date | Apr 27, 2017 |
Publication Date | Jul 31, 2017 |
Deposit Date | May 4, 2017 |
Publicly Available Date | May 4, 2017 |
Journal | Breast Cancer Research and Treatment |
Print ISSN | 0167-6806 |
Electronic ISSN | 1573-7217 |
Publisher | Springer Verlag |
Peer Reviewed | Peer Reviewed |
Volume | 164 |
Issue | 2 |
DOI | https://doi.org/10.1007/s10549-017-4267-8 |
Keywords | CDC42, Immunohistochemistry, Luminal breast cancer, prognosis |
Public URL | https://nottingham-repository.worktribe.com/output/874942 |
Publisher URL | https://link.springer.com/article/10.1007%2Fs10549-017-4267-8 |
Contract Date | May 4, 2017 |
Files
s10549-017-4267-8 Pheno.pdf
(764 Kb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
You might also like
PPP1R15A-mediated dephosphorylation of eIF2α is unaffected by Sephin1 or Guanabenz
(2017)
Journal Article
Nostrin as a marker related to low grade and better prognosis in breast cancer
(2016)
Presentation / Conference Contribution
Breast cancer intratumour heterogeneity: current status and clinical implications
(2018)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search